Melbourne to Host Colossal Australia: A New Frontier in De-Extinction

Colossal Biosciences, a Texas-based de‑extinction biotech firm valued at over USD 10 billion, has officially launched its first international arm—Colossal Australia—at the University of Melbourne. Leading the charge is Professor Andrew Pask, the university’s renowned developmental biologist, who will now serve as Colossal’s Chief Biology Officer. His Thylacine Integrated Genomic Restoration Research (TIGGR) Lab will be subsumed into this new venture, consolidating all Colossal‑affiliated projects in Australia under one roof. The Melbourne-based team will pursue ambitious de‑extinction and conservation initiatives, aiming to bring back species like the thylacine (Tasmanian tiger), dodo, giant moa, and woolly mammoth. The expansion is backed by an eight‑figure USD investment and highlights Australia as Colossal’s first global outpost.